| dbo:abstract |
بيرغوليد (بالإنجليزية: Pergolide) (الأسماء التجارية بيرماكس ،براسيند) هي ناهضة مستقبل دوبامين معتمدة على الإرغولين تُستخدم في بعض البلدان لعلاج مرض باركنسون. يصاحب مرض باركنسون انخفاض في نشاط الدوبامين في المادة السوداء من الدماغ. ويعمل البيرغوليد على العديد من نفس المستقبلات التي يعمل عليها الدوبامين ويقوم بزيادة نشاط المستقبل. حُصِل على براءة اختراعه سنة 1978 وتم اعتماده للاستخدام الطبي سنة 1898. تم سحب بيرغوليد سنة 2007 من سوق الولايات المتحدة للاستخدام البشري بعد العديد من الدراسات المنشورة التي أظهرت رابطا بين هذا الدواء وزيادةٍ في معدل الإصابة بالداء القلبي الصمامي. مع ذلك، يتم تسويق هيئة بيطرية من بيرغوليد تحت الاسم التجاري براسيند، وتم السماح بها لمعالجة (PPID) المعروف كذلك بمتلازمة كوشينغ الخيلية (ECS) في الأحصنة. (ar) Pergolid ist ein Arzneistoff, der zur Therapie der Parkinson-Krankheit eingesetzt wird. Seine pharmakologischen Effekte vermittelt dieser von Mutterkornalkaloiden abgeleitete Arzneistoff über eine Aktivierung von Dopamin-Rezeptoren (Dopaminagonist). (de) La pergolida es un agonista de los receptores de dopamina basada en la ergolina, que se utiliza en algunos países para el tratamiento de la enfermedad de Parkinson. La enfermedad de Parkinson se asocia con niveles bajos del neurotransmisor dopamina en el cerebro. La pergolida tiene algunos efectos similares a la dopamina en el cuerpo. (es) Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine activity in the substantia nigra of the brain. Pergolide acts on many of the same receptors as dopamine to increase receptor activity. It was patented in 1978 and approved for medical use in 1989. In 2007, pergolide was withdrawn from the U.S. market for human use after several published studies revealed a link between the drug and increased rates of valvular heart disease. However, a veterinary form of pergolide, marketed under the trade name Prascend, is permitted for the treatment of pituitary pars intermedia dysfunction (PPID) also known as equine Cushing's syndrome (ECS) in horses. (en) Il pergolide è un principio attivo che si utilizza nel trattamento della malattia di Parkinson, utilizzata anche in combinazione con il levodopa quando gli agonisti dei recettori della dopamina non hanno dimostrato effetti positivi. (it) |
| dbo:alternativeName |
Permax, Prascend (veterinary), others (en) |
| dbo:casNumber |
66104-22-1 |
| dbo:chEBI |
63617 |
| dbo:chEMBL |
531 |
| dbo:drugbank |
DB01186 |
| dbo:fdaUniiCode |
24MJ822NZ9 |
| dbo:kegg |
D08339 |
| dbo:pubchem |
47811 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Pergolid_Structural_Formulae_V.1.svg?width=300 |
| dbo:wikiPageID |
622942 (xsd:integer) |
| dbo:wikiPageLength |
17110 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1116397933 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cabergoline dbr:Carcinoid_syndrome dbr:Boehringer_Ingelheim dbc:D2-receptor_agonists dbc:D3_receptor_agonists dbc:D4_receptor_agonists dbr:Lisuride dbr:Dopamine_receptor dbr:Dopamine_receptor_D1 dbr:Dopamine_receptor_D2 dbr:Pars_intermedia dbc:Thioethers dbr:Oral_administration dbr:Substantia_nigra dbr:Brain dbr:Pharmacodynamics dbr:Pituitary_Pars_Intermedia_Dysfunction dbr:Muscarinic_acetylcholine_receptor_M1 dbc:Ergolines dbr:Agonist dbr:5-HT1A_receptor dbr:5-HT1B_receptor dbr:5-HT1D_receptor dbr:5-HT2A_receptor dbr:5-HT2B_receptor dbr:5-HT2C_receptor dbr:5-HT6_receptor dbr:5-HT7_receptor dbr:Ergoline dbr:Ergotamine dbr:Fenfluramine dbr:Food_and_Drug_Administration dbc:Prolactin_inhibitors dbr:Parkinson's_disease dbr:Cardiac_fibrosis dbr:Receptor_(biochemistry) dbc:5-HT2B_agonists dbc:Withdrawn_drugs dbr:Hallucinogenic dbc:Equine_medications dbr:Affinity_(pharmacology) dbr:Therapy dbr:Dopamine dbr:Dopamine_receptor_agonist dbc:Dopamine_receptor_modulators dbr:Pituitary_adenoma dbr:D1_receptor dbr:D2L_receptor dbr:D2S_receptor dbr:D3_receptor dbr:D4_receptor dbr:D5_receptor dbr:H1_receptor dbr:Methysergide dbr:Sex_addiction dbr:Raynaud's_phenomenon dbr:Valvular_heart_disease dbr:Pituitary_pars_intermedia_dysfunction dbr:Sigma-2_receptor dbr:Sigma-1_receptor dbr:Gambling_addiction dbr:Serotonin_receptor dbr:5-HT1A dbr:5-HT1B dbr:5-HT2A dbr:5-HT2B dbr:5-HT2C dbr:Cardiac_valvulopathy dbr:Medical_use dbr:Α1A-Adrenergic_receptor dbr:Α1B-Adrenergic_receptor dbr:Α1D-Adrenergic_receptor dbr:Α2A-Adrenergic_receptor dbr:Α2B-Adrenergic_receptor dbr:Α2C-Adrenergic_receptor dbr:Α2D-Adrenergic_receptor dbr:Β1-Adrenergic_receptor dbr:Β2-Adrenergic_receptor |
| dbp:atcPrefix |
N04 (en) |
| dbp:atcSuffix |
BC02 (en) |
| dbp:c |
19 (xsd:integer) |
| dbp:casNumber |
66104 (xsd:integer) |
| dbp:chebi |
63617 (xsd:integer) |
| dbp:chembl |
531 (xsd:integer) |
| dbp:chemspiderid |
43503 (xsd:integer) |
| dbp:drugbank |
DB01186 (en) |
| dbp:eliminationHalfLife |
97200.0 (dbd:second) |
| dbp:h |
26 (xsd:integer) |
| dbp:iupacName |
-9 (xsd:integer) |
| dbp:iupharLigand |
48 (xsd:integer) |
| dbp:kegg |
D08339 (en) |
| dbp:legalUsComment |
Veterinary use only, withdrawn for human use (en) |
| dbp:metabolism |
Extensively Hepatic (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:pregnancyCategory |
B (en) |
| dbp:proteinBound |
90.0 (dbd:perCent) |
| dbp:pubchem |
47811 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:s |
1 (xsd:integer) |
| dbp:smiles |
[H][C@]12C[C@@H]CN[C@]1Cc3c[nH]c4cccc2c34 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
YEHCICAEULNIGD-MZMPZRCHSA-N (en) |
| dbp:synonyms |
8 (xsd:integer) |
| dbp:title |
dbr:Pharmacodynamics Medical uses (en) |
| dbp:titlestyle |
background:#ccccff (en) |
| dbp:tradename |
Permax, Prascend , others (en) |
| dbp:unii |
24 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
464199003 (xsd:integer) |
| dbp:width |
200 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Adrenergic_receptor_modulators dbt:Citation_needed dbt:Drugbox dbt:Hallucinogens dbt:Navboxes dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Antiparkinson dbt:Prolactin_inhibitors_and_anti-inflammatory_products_for_vaginal_administration dbt:Prolactin_receptor_modulators dbt:Drugs.com dbt:Dopamine_receptor_modulators dbt:Ergolines |
| dct:subject |
dbc:D2-receptor_agonists dbc:D3_receptor_agonists dbc:D4_receptor_agonists dbc:Thioethers dbc:Ergolines dbc:Prolactin_inhibitors dbc:5-HT2B_agonists dbc:Withdrawn_drugs dbc:Equine_medications dbc:Dopamine_receptor_modulators |
| gold:hypernym |
dbr:Agonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAntiparkinsonianAgents yago:WikicatMolecularFormulas yago:WikicatWithdrawnDrugs yago:Abstraction100002137 yago:Agent109190918 yago:Agent114778436 yago:CausalAgent100007347 yago:Communication100033020 yago:Drug103247620 yago:Formula106816935 yago:Matter100020827 yago:Medicine103740161 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 dbo:Drug yago:Statement106722453 yago:Substance100020090 yago:WikicatEquineMedications umbel-rc:DrugProduct |
| rdfs:comment |
Pergolid ist ein Arzneistoff, der zur Therapie der Parkinson-Krankheit eingesetzt wird. Seine pharmakologischen Effekte vermittelt dieser von Mutterkornalkaloiden abgeleitete Arzneistoff über eine Aktivierung von Dopamin-Rezeptoren (Dopaminagonist). (de) La pergolida es un agonista de los receptores de dopamina basada en la ergolina, que se utiliza en algunos países para el tratamiento de la enfermedad de Parkinson. La enfermedad de Parkinson se asocia con niveles bajos del neurotransmisor dopamina en el cerebro. La pergolida tiene algunos efectos similares a la dopamina en el cuerpo. (es) Il pergolide è un principio attivo che si utilizza nel trattamento della malattia di Parkinson, utilizzata anche in combinazione con il levodopa quando gli agonisti dei recettori della dopamina non hanno dimostrato effetti positivi. (it) بيرغوليد (بالإنجليزية: Pergolide) (الأسماء التجارية بيرماكس ،براسيند) هي ناهضة مستقبل دوبامين معتمدة على الإرغولين تُستخدم في بعض البلدان لعلاج مرض باركنسون. يصاحب مرض باركنسون انخفاض في نشاط الدوبامين في المادة السوداء من الدماغ. ويعمل البيرغوليد على العديد من نفس المستقبلات التي يعمل عليها الدوبامين ويقوم بزيادة نشاط المستقبل. (ar) Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine activity in the substantia nigra of the brain. Pergolide acts on many of the same receptors as dopamine to increase receptor activity. (en) |
| rdfs:label |
بيرغوليد (ar) Pergolid (de) Pergolida (es) Pergolide (it) Pergolide (en) |
| owl:sameAs |
freebase:Pergolide wikidata:Pergolide dbpedia-ar:Pergolide http://azb.dbpedia.org/resource/پرقولید dbpedia-cy:Pergolide dbpedia-de:Pergolide dbpedia-es:Pergolide dbpedia-it:Pergolide dbpedia-ro:Pergolide dbpedia-sh:Pergolide dbpedia-sr:Pergolide https://global.dbpedia.org/id/3r1Uf http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01186 http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4745 yago-res:Pergolide |
| prov:wasDerivedFrom |
wikipedia-en:Pergolide?oldid=1116397933&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Pergolid_Structural_Formulae_V.1.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Pergolide |
| is dbo:wikiPageRedirects of |
dbr:Permax dbr:C19H26N2S dbr:ATC_code_N04BC02 dbr:ATCvet_code_QN04BC02 dbr:Pergolide_mesylate |
| is dbo:wikiPageWikiLink of |
dbr:Cabergoline dbr:Prolactinoma dbr:Rotigotine dbr:List_of_dopaminergic_drugs dbr:Parkinsonian_gait dbr:Prolactin_modulator dbr:Lisuride dbr:Dopamine_agonist dbr:Dopamine_receptor_D1 dbr:Dopamine_receptor_D3 dbr:Dopaminergic dbr:Permax dbr:Erythromelalgia dbr:Ergot dbr:Lysergamides dbr:Management_of_Parkinson's_disease dbr:Management_of_Tourette_syndrome dbr:Fungal_isolate dbr:Medicinal_fungi dbr:Bromocriptine dbr:C19H26N2S dbr:Tremor dbr:5-HT2B_receptor dbr:Edmund_Kornfeld dbr:Ergoline dbr:Parkinson's_disease dbr:Cardiac_fibrosis dbr:List_of_MeSH_codes_(D03) dbr:ATC_code_N04BC02 dbr:ATCvet_code_QN04BC02 dbr:Hyperprolactinaemia dbr:Hypoprolactinemia dbr:ATC_code_N04 dbr:Dihydroergocryptine dbr:Dopamine dbr:Fibrothorax dbr:Bruxism dbr:Serotonin dbr:Valvular_heart_disease dbr:List_of_veterinary_drugs dbr:List_of_withdrawn_drugs dbr:Somnolence dbr:Pituitary_pars_intermedia_dysfunction dbr:Periodic_limb_movement_disorder dbr:Serotonin_receptor_agonist dbr:List_of_drugs:_Pb–Pe dbr:Pergolide_mesylate |
| is foaf:primaryTopic of |
wikipedia-en:Pergolide |
